Skip to main content

Table 6 LS-SBA - overall survival by prognostic factors (only patient who received first line chemotherapy)

From: Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience

   Number events/Number subjects 1 Year survival (95% CI) Hazard ratio (95% CI) p-value
Gender Male 16/24 57.1 (35.7 – 78.5) 1.06 (0.53 – 2.11) 0.869
  Female 17/22 64.6 (43.4 – 85.8) -  
Primary tumour Duodenum 26/34 56.5 (38.5 – 74.5) - (0.130)
  Jejunum 5/7 71.4 (37.9 – 100) 0.55 (0.21 – 1.45) 0.224
  Ileum 2/5 75.0 (32.5 – 100) 0.27 (0.06 – 1.17) 0.080
Disease status Locally Advanced 9/13 67.7 (41.4 – 94.0) -  
  Metastatic 22/27 51.6 (31.8 – 71.4) 1.99 (0.90 - 4.42) 0.089
Chemo 1ST line Doublet 11/18 52.6 (28.5 – 76.7) -  
  Triplet 19/23 64.8 (43.6 – 86.0) 1.67 (0.78 – 3.55) 0.185
Chemo 2nd line No 18/17 27.9 (8.1 – 47.7) -  
  Yes 19/19 31.6 (10.6 – 52.6) 1.17 (0.61 – 2.24) 0.633
Small Bowel Obstruction None 21/28 55.3 (35.3 – 75.3) -  
  Present 4/8 51.4 (11.4 – 91.4) 0.55 (0.19 – 1.61) 0.274
Weight loss None 13/23 49.4 (25.1 – 73.7) -  
  Present 12/13 61.5 (35.0 – 88.0) 1.11 (0.50 – 2.45) 0.803
CEA at baseline Normal 5/9 66.7 (35.9 - 97.5) -  
  Abnormal 23/27 52.2 (32.4 – 72.0) 3.15 (1.15 – 8.60) 0.025
Hemoglobin Normal 8/10 90.0 (71.4 – 100) -  
  Abnormal 22/29 46.2 (26.6 – 65.8) 1.51 (0.67 – 3.43) 0.323
Albumin Normal 15/22 80.4 (63.2 – 97.6) -  
  Abnormal 15/17 32.1 (9.2 – 55.0) 2.15 (1.03 – 4.46) 0.041
LDH Normal 13/18 63.6 (39.9 – 87.3) -  
  Abnormal 13/16 53.3 (28.0 – 78.6) 1.31 (0.59 – 2.87) 0.507
Alk.Ph Normal 16/23 70.5 (50.3 – 90.7) -  
  Abnormal 14/16 43.8 (19.5 – 68.1) 1.45 (0.70 – 2.99) 0.320
ALT Normal 23/30 63.4 (45.2 – 81.6) -  
  Abnormal 6/8 31.3 (0 – 66.2) 1.96 (0.77 – 4.96) 0.156
Platelets Normal 15/24 73.4 (55.0 – 91.8) -  
  Abnormal 16/17 38.0 (14.1 – 61.9) 2.85 (1.34 – 6.08) 0.007